Second license deal with Amgen to bring ImmunoGen another $35M

By Mass High Tech staff

Video Gallery

Funding drugs for rare diseases

MHT's Julie Donnelly: Life science startups finding investments

MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban

AMAG adds board members amid 'strategic alternative' talks [February 8, 2012]

Navidea expands from Ohio into Andover office [February 8, 2012]

Synchroneuron focuses new funds on movement disorder drug [February 7, 2012]

Rib-X lands $3M milestone pay from Sanofi deal [February 7, 2012]

Waltham biotechnology firm ImmunoGen Inc. has announced a second license granted to Amgen Inc. for its maytansinoid Targeted Antibody Payload technology for an undisclosed target. The deal promises a $1 million upfront payment to ImmunoGen, with up to $34 million in milestone payments and additional royalties — the same agreement the company had with Amgen in September when it licensed the technology for a different undisclosed target.

ImmunoGen’s TAP technology relies on antibodies to deliver cell-killing agents to cancer targets.

As part of the agreement, Thousand Oaks, Calif.-based Amgen will be responsible for the development, manufacturing and marketing of any products related to the license.

This license was taken under an agreement established in 2000 between ImmunoGen (Nasdaq: IMGN) and Abgenix Inc., which later was acquired by Amgen.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.